Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.48 |
| ▸ | GABRD | O14764 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.48 |
| ▸ | GABRE | P78334 | 2/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.48 |
| ▸ | NOS3 | P29474 | 2/20 | 0.45 |
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9610886 | 0.77 | SMN1; SMN2 (0.45) | GABRA1GABRA5SMN1; SMN2RAB9A | |
| SCHEMBL30279718 | 0.76 | — | — | |
| SCHEMBL312816 | 0.76 | — | — | |
| SCHEMBL30185830 | 0.75 | ALDH1A1 (0.47) | KDM4ESMN1; SMN2 | |
| SCHEMBL27876174 | 0.75 | CYP11B1 (0.42) | SMN1; SMN2RAB9A | |
| SCHEMBL1146035 | 0.75 | ALDH1A1 (0.47) | KDM4ESMN1; SMN2 | |
| SCHEMBL12336888 | 0.73 | HRH3 (0.40) | NOS3NOS2KDM4ESMN1; SMN2NOS1 | |
| SCHEMBL318570 | 0.73 | — | — | |
| SCHEMBL29911003 | 0.73 | — | — | |
| SCHEMBL294092 | 0.72 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | GABRP 2556/4885GABRD 3538/4885GABRA1 4177/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | GABRP 2556/4885GABRD 3538/4885GABRA1 4177/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | GABRP 3999/4885GABRD 4186/4885GABRA1 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.